Home > Cardiology > ACC 2021 > Heart Failure and Cardiomyopathy > PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events

PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events

Presented By
Prof. Marc Pfeffer, Brigham and Women’s Hospital, USA
Conference
ACC 2021
Trial
Phase 3, PARADISE-MI
Sacubitril/valsartan did not reduce the rate of cardiovascular (CV) death, heart failure (HF) hospitalisation, or HF in outpatients after acute myocardial infarction (MI) when compared with ramipril according to initial findings of the phase 3 PARADISE-MI trial [1]. Patients who have experienced MI are known to be at risk for subsequently developing HF. PARADISE-MI (NCT02924727) aimed to evaluate the efficacy and safety of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, compared with ramipril, an angiotensin-converting enzyme (ACE) inhibitor, in preventing the development of HF and CV death following MI [2]. PARADISE-MI was a multicentre, randomised, double-blind, active-controlled, parallel-group, phase 3 study, in which 5,669 patients with left ventricular systoli...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on